Technical Analysis for UCBJY - UCB SA

Grade Last Price % Change Price Change
B 53.92 -0.59% -0.3200
UCBJY closed up 0.82 percent on Thursday, December 2, 2021, on 2.0 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical UCBJY trend table...

Date Alert Name Type % Chg
Slingshot Bearish Bearish Swing Setup -0.59%
Oversold Stochastic Weakness -0.59%
180 Bearish Setup Bearish Swing Setup 0.22%
Down 3 Days in a Row Weakness 0.22%
Down 4 Days in a Row Weakness 0.22%
Oversold Stochastic Weakness 0.22%
Down 3 Days in a Row Weakness -1.43%
Oversold Stochastic Weakness -1.43%
Narrow Range Bar Range Contraction -1.77%
NR7 Range Contraction -1.77%
Older End-of-Day Signals for UCBJY ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 1% about 4 hours ago
Slingshot Bearish Entry about 4 hours ago
Fell Below Previous Day's Low about 4 hours ago
Down 1% 7 days ago
Rose Above Previous Day's High 7 days ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


UCB SA Description

UCB SA, a biopharmaceutical company, develops therapies and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, nayzilam, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; bimekizumab for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition , the company is involved in developing padsevonil for the treatment of drug-resistant epilepsy; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis immune-mediated necrotizing myopathy; staccato alprazolam to treat active epileptic seizure; and UCB0107 to treat tauopathies and progressive supranuclear palsy. Further, it engages in contract manufacturing activities. The company has a multi-year collaboration agreement with Stanford Medicine to enhance patient value for people living with severe diseases. UCB SA has collaboration agreements with Sanofi, Amgen, Biogen, Otsuka, and The company operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. The company was founded in 1928 and is headquartered in Brussels, Belgium.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Medical Specialties Clinical Medicine Biopharmaceutical Arthritis Parkinson's Disease Autoimmune Diseases Rheumatoid Arthritis Monoclonal Antibodies Psoriasis Osteoporosis Epilepsy Allergies Rheumatology Crohn's Disease Plaque Psoriasis Immunosuppressants Parkinson Seizure Immune Thrombocytopenia Myasthenia Gravis Psoriatic Arthritis Ankylosing Spondylitis Chronic Inflammatory Demyelinating Polyneuropathy Progressive Supranuclear Palsy Systemic Lupus Erythematosus Treatment Of Osteoporosis Active Epileptic Seizure Alprazolam Certolizumab Pegol Cimzia Contract Manufacturing Activities Drug Resistant Epilepsy Hidradenitis Suppurativa Immune Mediated Necrotizing Myopathy Immunology Diseases Inflammatory Tnf Mediated Diseases Keppra Neupro Restless Legs Syndrome Severe Diseases Tauopathies Therapies And Solutions Ucb Vimpat Xyzal Zyrtec

Is UCBJY a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 61.96
52 Week Low 44.41
Average Volume 10,801
200-Day Moving Average 52.8600
50-Day Moving Average 57.8129
20-Day Moving Average 57.9134
10-Day Moving Average 55.5200
Average True Range 1.0980
ADX 22.95
+DI 22.4144
-DI 37.9214
Chandelier Exit (Long, 3 ATRs) 58.6660
Chandelier Exit (Short, 3 ATRs) 57.0640
Upper Bollinger Bands 63.1912
Lower Bollinger Band 52.6356
Percent B (%b) 0.15
BandWidth 18.2265
MACD Line -1.2122
MACD Signal Line -0.6585
MACD Histogram -0.5537
Fundamentals Value
Market Cap 20.51 Billion
Num Shares 378 Million
EPS 2.29
Price-to-Earnings (P/E) Ratio 23.69
Price-to-Sales 1.44
Price-to-Book 2.06
PEG Ratio 12.01
Dividend 1.27
Dividend Yield 2.34%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 55.2300
Resistance 3 (R3) 55.3333 55.1067 55.0650
Resistance 2 (R2) 55.1067 54.8545 55.0550 55.0100
Resistance 1 (R1) 54.6733 54.6988 54.5600 54.5700 54.9550
Pivot Point 54.4467 54.4467 54.3900 54.3950 54.4467
Support 1 (S1) 54.0133 54.1945 53.9000 53.9100 53.5250
Support 2 (S2) 53.7867 54.0388 53.7350 53.4700
Support 3 (S3) 53.3533 53.7867 53.4150
Support 4 (S4) 53.2500